STVNStevanato Group S.p.A.
Price
-27%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, growth steady, the market undecided.
We are a leading global provider of drug containment, drug delivery and diagnostic solutions as well as engineering solutions to the pharmaceutical, biotechnology and life sciences industries. We deliver an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug product life cycle from development to clinical and commercial stages. Our core capabilities in scientific research and development, our commitment to technical innovation and our engineering excellence are central to our ability to offer value-added solutions to our clients.
In the company’s own words · 20-F filed Mar 4, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
For the full year FY2025, revenue was €1.19B (+7.4% year on year) and net income €140M.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Instruments & Supplies
Ranks #4 of 21 by RyuScore